Rockefeller Capital Management L.P. Acquires 5,541 Shares of Masimo Co. (NASDAQ:MASI)

Rockefeller Capital Management L.P. boosted its position in Masimo Co. (NASDAQ:MASI - Free Report) by 4.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 137,393 shares of the medical equipment provider's stock after purchasing an additional 5,541 shares during the quarter. Rockefeller Capital Management L.P. owned approximately 0.26% of Masimo worth $18,321,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. NBC Securities Inc. grew its position in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC grew its holdings in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. Lazard Asset Management LLC boosted its position in shares of Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 573 shares in the last quarter. Finally, HHM Wealth Advisors LLC boosted its position in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after purchasing an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Stock Performance

Shares of MASI traded down $0.85 during mid-day trading on Monday, hitting $171.69. 334,853 shares of the company traded hands, compared to its average volume of 674,040. The stock has a market cap of $9.19 billion, a price-to-earnings ratio of 118.41 and a beta of 0.97. The stock has a 50-day moving average price of $150.17 and a two-hundred day moving average price of $130.27. Masimo Co. has a 1 year low of $96.40 and a 1 year high of $178.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period in the previous year, the business earned $0.63 EPS. The company's quarterly revenue was up 5.4% compared to the same quarter last year. Equities analysts anticipate that Masimo Co. will post 4.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MASI. Piper Sandler lifted their price objective on Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target on the stock in a research note on Wednesday, November 6th. Stifel Nicolaus restated a "buy" rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Wells Fargo & Company upped their target price on shares of Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has an average rating of "Moderate Buy" and a consensus price target of $167.00.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.